Neuroleptic Malignant Syndrome: Causes and Treatment

Neuroleptic Malignant Syndrome (NMS) is a severe and potentially life-threatening medical complication associated with the use of antipsychotic or neuroleptic drugs. Although rare, this syndrome is considered a medical emergency that requires immediate treatment. Patients taking antipsychotic medications to manage mental disorders such as schizophrenia or bipolar disorder are at risk of developing NMS, though it can also occur in patients taking medications for other neurological conditions.

What is Neuroleptic Malignant Syndrome?

Neuroleptic Malignant Syndrome (NMS) is a severe adverse reaction to neuroleptic medications, such as antipsychotics, that affect the central nervous system. Antipsychotics are drugs used to treat severe psychiatric disorders and act primarily by blocking dopamine receptors in the brain. In NMS, the response to dopamine blockade is exaggerated, triggering a cascade of events that result in autonomic nervous system dysfunction and severe muscle rigidity.

This syndrome can develop rapidly, and symptoms progress quickly if left untreated. It affects both the motor system and the autonomic system and can be fatal in a significant percentage of cases.

Causes of Neuroleptic Malignant Syndrome

NMS is mainly caused by the use of antipsychotic or neuroleptic medications, which interfere with dopamine regulation in the brain. Antipsychotics, especially first-generation agents, are most strongly associated with the development of this syndrome, although second-generation antipsychotics can also trigger it.

The most common causes include:

1. Use of antipsychotics: Medications such as haloperidol, chlorpromazine, and fluphenazine are among the most implicated. However, other atypical antipsychotics, such as risperidone or olanzapine, can also cause it.
2. Dose change or adjustment: Rapid increases in the dose of neuroleptics or intramuscular administration of these medications can increase the risk of developing NMS.
3. Abrupt discontinuation of dopaminergic medications: Patients who are taking drugs to increase dopamine levels, such as in Parkinson’s disease, may develop NMS if the treatment is stopped abruptly.
4. Predisposing factors: Some factors can predispose a person to develop the syndrome, such as dehydration, extreme physical exhaustion, underlying mental disorders, and medical conditions such as infections.

Symptoms of Neuroleptic Malignant Syndrome

The symptoms of NMS usually appear within days or weeks after starting treatment with antipsychotics or following a change in dosage. The clinical presentation includes a set of symptoms related to severe muscle rigidity, autonomic nervous system dysfunction, and mental status changes. The key symptoms are:

1. Extreme muscle rigidity: Generalized muscle stiffness is one of the main symptoms and can make patient movement difficult.
2. High fever: One of the most notable features of NMS is a high fever, which can exceed 40°C (104°F) due to autonomic nervous system dysfunction.
3. Altered mental status: Patients may experience confusion, agitation, lethargy, and in the most severe cases may even fall into a coma.
4. Autonomic dysfunction: It manifests as unstable blood pressure, tachycardia, excessive sweating, and respiratory disturbances. These symptoms can be dangerous if not properly managed.
5. Extrapyramidal symptoms: Abnormal movements, tremors, and exaggerated reflexes are also common.

Diagnosis of Neuroleptic Malignant Syndrome

The diagnosis of Neuroleptic Malignant Syndrome is clinical and based on the combination of characteristic symptoms, medical history, and recent use of neuroleptics. There is no specific laboratory test to diagnose NMS, but certain examinations can be useful to confirm the diagnosis and rule out other conditions. Some tests include:

• Laboratory tests: Elevated levels of creatine kinase (CK) in the blood are usually observed due to muscle breakdown. Leukocytosis, electrolyte imbalances, and signs of kidney damage may also be present.
• Electroencephalogram (EEG): In some cases, an EEG may be performed to rule out other causes of mental status changes.
• Brain imaging: Although it is not commonly required for the diagnosis of NMS, studies such as magnetic resonance imaging (MRI) or computed tomography (CT) may be used if other underlying neurological problems are suspected.

The differential diagnosis includes other conditions such as central nervous system infections, malignant hyperthermia, and serotonin syndromes.

Treatment of Neuroleptic Malignant Syndrome

The treatment of NMS is a medical emergency and requires the immediate discontinuation of the causative drug. The main goal is to stabilize the patient and reduce symptoms. Treatment options include:

1. Discontinuation of antipsychotics: Immediately stopping the use of the antipsychotic drug is the most important step.
2. Life support: In severe cases, admission to an intensive care unit (ICU) may be necessary to monitor vital signs and correct autonomic dysfunction.
3. Specific medication:
   • Dantrolene: A muscle relaxant that can be effective in reducing muscle rigidity and controlling fever.
   • Bromocriptine: A dopamine agonist that helps restore dopamine levels in the brain and relieve symptoms.
   • Amantadine: It can also be used to improve dopamine levels.
4. Complication management: In patients who develop kidney damage due to rhabdomyolysis (muscle breakdown), intensive hydration or even dialysis may be required.

Prompt and proper management of NMS is crucial to prevent serious complications and improve the patient’s prognosis.

Prognosis and complications

The prognosis of Neuroleptic Malignant Syndrome varies depending on how quickly treatment is initiated and the severity of the case. If detected early and managed properly, most patients recover without permanent sequelae. However, in severe cases, complications may include:

• Kidney damage from rhabdomyolysis
• Multiple organ failure due to autonomic dysfunction
• Brain damage if a prolonged coma occurs

The mortality associated with NMS has decreased considerably with appropriate treatment, but it remains a serious condition that requires rapid intervention.

Conclusion

Neuroleptic Malignant Syndrome (NMS) is a rare but dangerous complication of antipsychotic use, which can affect both the central nervous system and the autonomic system. While antipsychotics are essential for the treatment of many psychiatric disorders, it is crucial to remain alert to the early signs of NMS in order to prevent serious complications.

Early diagnosis, discontinuation of the causative drug, and intensive management are essential to ensure patient recovery. With advances in treatment and increased awareness of this condition, the prognosis for patients with NMS has significantly improved.

If you would like more information about NeuroAiD II, please fill out this contact form.